Aspen expects Canada nod for generic targeting Novo's Ozempic by September
Source: SeekingAlpha
2026-03-03 12:09:49 ET
More on Novo Nordisk, Aspen Pharmacare
- Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk
- Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable
- Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks
- Novo’s China obesity drug posts positive mid-stage trial results
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
Read the full article on Seeking Alpha
For further details see:
Aspen expects Canada nod for generic targeting Novo’s Ozempic by September
Novo Nordisk - Class B
NASDAQ: NONOF
NONOF Trading
-0.75% G/L:
$38.46 Last:
16,693 Volume:
$38.50 Open:
NONOF Latest News
NONOF Stock Data
$217,715,792,624
1,607,906,287
N/A
1546
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
